Literature DB >> 21437912

Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations.

Ottavio Rena1, Luciano R Boldorini, Erica Gaudino, Caterina Casadio.   

Abstract

BACKGROUND: To evaluate epidermal growth factor receptor (EGFR) phenotypic expression and related gene status in malignant pleural mesothelioma (MPM) and to correlate the results with patients' prognosis.
METHOD: Eighty-three cases of MPM specimens were submitted to immunohistochemical (IHC) staining to evaluate the expression of EGFR protein; positive cases were submitted to fluorescence in situ hybridization (FISH) to investigate the gene status. Results were correlated with clinico-pathological characteristics and long-term survival.
RESULTS: Thirty-eight cases (46%) demonstrated a positive IHC reaction [30/57 (52%) epithelial and 8/20 (40%) biphasic whereas sarcomatous MPM were negative]. No association was recorded between EGFR IHC positive staining and age, gender, or asbestos exposure. Three out of 38 (8%) cases submitted to FISH were positive revealing gene amplification or polysomy. Mean follow-up was 15.4  months (range 2-44). Epithelial subtype only was confirmed to affect prognosis (2-years survival rate 40 vs. 18% for non-epithelial subtype, P = 0.042). When epithelial MPM patients were considered, IHC EGFR positive staining was demonstrated to be a negative prognostic factor (2-years survival rate 26 vs. 60% for IHC EGFR negative staining; P = 0.026).
CONCLUSIONS: EGFR overexpression is identified by IHC in 52% of epithelial MPM and is demonstrated to be a factor negatively affecting prognosis. Phenotypic overexpression seems not to be related to gene status alteration.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21437912     DOI: 10.1002/jso.21901

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

1.  Modeling Epidermal Growth Factor Inhibitor-mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture.

Authors:  Gwendolyn Cramer; Michael Shin; Sarah Hagan; Sharyn I Katz; Charles B Simone; Theresa M Busch; Keith A Cengel
Journal:  Photochem Photobiol       Date:  2019-01-07       Impact factor: 3.421

2.  DNA copy number gains in malignant pleural mesothelioma.

Authors:  Masashi Furukawa; Shinichi Toyooka; Tatsuro Hayashi; Hiromasa Yamamoto; Nobukazu Fujimoto; Junichi Soh; Shinsuke Hashida; Kazuhiko Shien; Hiroaki Asano; Keisuke Aoe; Kazunori Okabe; Harvey I Pass; Kazunori Tsukuda; Takumi Kishimoto; Shinichiro Miyoshi
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

3.  Leser–Trélat syndrome in malignant mesothelioma and pulmonary adenocarcinoma: is the EGFR pathway part of the syndrome?

Authors:  Rikke Karlin Jepsen; Anne Guldhammer Skov; Birgit Guldhammer Skov
Journal:  Virchows Arch       Date:  2014-01       Impact factor: 4.064

4.  Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Authors:  Susana Cedrés; Santiago Ponce-Aix; Jon Zugazagoitia; Irene Sansano; Ana Enguita; Alejandro Navarro-Mendivil; Alex Martinez-Marti; Pablo Martinez; Enriqueta Felip
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

5.  Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study.

Authors:  Till Plönes; Frank Beckers; Walburga Engel-Riedel; Erich Stoelben; Michael Brockmann; Verena Schildgen; Oliver Schildgen
Journal:  BMC Res Notes       Date:  2014-08-19

6.  miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.

Authors:  Marissa Williams; Michaela B Kirschner; Yuen Yee Cheng; Jacky Hanh; Jocelyn Weiss; Nancy Mugridge; Casey M Wright; Anthony Linton; Steven C Kao; J James B Edelman; Michael P Vallely; Brian C McCaughan; Wendy Cooper; Sonja Klebe; Ruby C Y Lin; Himanshu Brahmbhatt; Jennifer MacDiarmid; Nico van Zandwijk; Glen Reid
Journal:  Oncotarget       Date:  2015-09-15

7.  Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma.

Authors:  R Mezzapelle; U Miglio; O Rena; A Paganotti; S Allegrini; J Antona; F Molinari; M Frattini; G Monga; O Alabiso; R Boldorini
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

8.  CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma.

Authors:  Vishwa Jeet Amatya; Yukio Takeshima; Keisuke Aoe; Nobukazu Fujimoto; Toshihiro Okamoto; Taketo Yamada; Takumi Kishimoto; Chikao Morimoto; Kouki Inai
Journal:  Oncol Rep       Date:  2012-10-31       Impact factor: 3.906

9.  Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

Authors:  Michaela B Kirschner; Emily Pulford; Mir Alireza Hoda; Anita Rozsas; Kim Griggs; Yuen Yee Cheng; J James B Edelman; Steven C Kao; Rebecca Hyland; Yawen Dong; Viktoria László; Thomas Klikovits; Michael P Vallely; Michael Grusch; Balazs Hegedus; Balazs Dome; Walter Klepetko; Nico van Zandwijk; Sonja Klebe; Glen Reid
Journal:  Br J Cancer       Date:  2015-08-11       Impact factor: 7.640

Review 10.  Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.

Authors:  Bhairavi Tolani; Luis A Acevedo; Ngoc T Hoang; Biao He
Journal:  Int J Mol Sci       Date:  2018-01-13       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.